公开(公告)号：US20240200027A1

公开(公告)日：2024-06-20

申请号：US18119682

申请日：2023-03-09

申请人： NUWACELL BIOTECHNOLOGIES CO., LTD.

发明人： Junying YU ,  Luyan JIAO ,  Yongqiang ZHAO ,  Ying ZHANG

IPC分类号： C12N5/0793

CPC分类号： C12N5/0619 ,  C12N2501/13 ,  C12N2501/15 ,  C12N2501/727

摘要： The present disclosure described herein provides, inter alia, an expansion method for expanding mDAPs and a culture medium and a coating matrix combination used in the expansion method, as well as a maturation method for maturing mDAPs and a culture medium used in the maturation method. The present disclosure also provides a substantially homogeneous population of mDAPs and a substantially homogeneous population of mDANs.

公开(公告)号：US11998617B2

公开(公告)日：2024-06-04

申请号：US17358774

申请日：2021-06-25

申请人： CURAMYS INC.

发明人： Jung-Joon Sung ,  Seung-Yong Seong ,  Hee-Woo Lee ,  Ki Yoon Kim

IPC分类号： A61K48/00 ,  A61K35/30 ,  A61K35/545 ,  A61P21/00 ,  A61P25/00 ,  C07K14/005 ,  C12N5/0735 ,  C12N5/074 ,  C12N5/0775 ,  C12N5/0793 ,  C12N5/12 ,  C12N5/16 ,  C12N9/24 ,  C12N15/85 ,  A61K38/00

CPC分类号： A61K48/005 ,  A61K35/30 ,  A61K35/545 ,  A61P21/00 ,  A61P25/00 ,  C07K14/005 ,  C12N5/0606 ,  C12N5/0619 ,  C12N5/0667 ,  C12N5/0696 ,  C12N5/12 ,  C12N5/16 ,  C12N9/2402 ,  C12N15/85 ,  A61K38/00 ,  C12N2760/18822 ,  C12N2760/18833

摘要： The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.

公开(公告)号：US20240108760A1

公开(公告)日：2024-04-04

申请号：US18273867

申请日：2022-01-25

申请人： TRAMES BIO, INC.

发明人： Annahita KERAVALA ,  Edward YEH ,  Albena KANTARDZHIEVA

IPC分类号： A61K48/00 ,  A61K9/00 ,  A61P25/08 ,  C12N5/0793 ,  C12N15/86

CPC分类号： A61K48/0016 ,  A61K9/0019 ,  A61P25/08 ,  C12N5/0619 ,  C12N15/86 ,  C12N2750/14143

摘要： The present disclosure provides compositions and methods for treating neuropathic pain or focal epilepsy. Further provided are AAV capsid polypeptides and/or nucleic acids suitable for transducing neurons related to neuropathic pain or focal epilepsy. The disclosure relates to AAV vectors comprising specific capsid polypeptides that provides desirable transduction efficiency and/or tropism for neurons responsible for neuropathic pain or focal epilepsy management.

公开(公告)号：US20240076613A1

公开(公告)日：2024-03-07

申请号：US18502516

申请日：2023-11-06

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Marine Prissette ,  Matthew Koss ,  Mathieu Desclaux ,  John McWhirter ,  Arijit Bhowmick ,  David Frendewey ,  Brian Zambrowicz ,  Claudia Racioppi

IPC分类号： C12N5/0793 ,  A61K9/00 ,  A61K48/00 ,  C12N15/113

CPC分类号： C12N5/0619 ,  A61K9/0019 ,  A61K48/0058 ,  C12N15/113 ,  C12N2310/11

摘要： BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.

公开(公告)号：US20240024368A1

公开(公告)日：2024-01-25

申请号：US18352730

申请日：2023-07-14

申请人： The Children's Medical Center Corporation

发明人： Zhigang HE ,  Shane HEGARTY ,  Feng TIAN ,  Joanna STANICKA ,  Songlin ZHOU

IPC分类号： A61K35/30 ,  A61P25/28 ,  C12N5/0793 ,  C12N15/11 ,  C12N9/22 ,  C12N15/90

CPC分类号： A61K35/30 ,  A61P25/28 ,  C12N5/0619 ,  C12N15/11 ,  C12N9/22 ,  C12N15/907 ,  C12N2310/20 ,  C12N2800/80

摘要： As described below, the present invention features compositions and methods for neuroprotection and/or neuroregeneration of damaged or degenerating neurons. In various embodiments, the compositions and methods of the present disclosure are used to treat a neurodegenerative disease and/or nervous system injury. The methods in various embodiments include reducing or eliminating activity or expression of a target gene(s) and/or a polypeptide(s) expressed by a target gene(s) in a neuron.

公开(公告)号：US20240010975A1

公开(公告)日：2024-01-11

申请号：US18254549

申请日：2021-05-10

申请人： ZHEJIANG HUODE BIOENGINEERING COMPANY LIMITED

发明人： Jing FAN ,  Anxin WANG ,  Fang REN ,  Qianyun LIU ,  Tan ZOU

IPC分类号： C12N5/0797 ,  C12N5/0793

CPC分类号： C12N5/0623 ,  C12N5/0619 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2501/727 ,  C12N2500/38 ,  C12N2501/13 ,  C12N2501/01 ,  C12N2533/52

摘要： The present application provides methods, cell culture media and combinations thereof for generating neural progenitor cells (NPCs), particularly human neural progenitor cells (hNPCs), from either embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), wherein the NPCs are particularly suitable for pre-clinical and clinical use.

公开(公告)号：US20240009248A1

公开(公告)日：2024-01-11

申请号：US18044288

申请日：2021-09-08

申请人： University Health Network

发明人： Michael G FEHLINGS ,  Mohammad KHAZAEI ,  Christopher S AHUJA

IPC分类号： A61K35/30 ,  C12N5/0793 ,  A61P25/28

CPC分类号： A61K35/30 ,  C12N5/0619 ,  A61P25/28 ,  C12N2506/45 ,  C12N2501/11 ,  C12N2501/42 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/415

摘要： Provided herein are methods of producing spNPCs from iPSCs or NPCs, cell populations, compositions comprising cell populations, and uses of spNPCs made using the methods described. The method can comprise: a. obtaining unpatterned NPCs, the unpatterned NPCs expressing neuroectodermal markers including Pax6 and Sox1; b. priming the unpatterned NPCs of step a; and c. patterning the primed unpatterned NPCs to produce spNPCS.

公开(公告)号：US20230416675A1

公开(公告)日：2023-12-28

申请号：US18038734

申请日：2020-11-25

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  SORBONNE UNIVERSITE ,  UNIVERSITÉ D'EVRY-VAL-D'ESSONNE ,  CENTRE D'ETUDE DES CELLULES SOUCHES (CECS) ,  UNIVERSITÉ PARIS-SACLAY

发明人： Stéphane NEDELEC ,  Cécile MARTINAT ,  Vincent MOUILLEAU ,  Célia VASLIN

IPC分类号： C12N5/0793

CPC分类号： C12N5/0619 ,  C12N2506/45 ,  C12N2501/41 ,  C12N2501/19 ,  C12N2501/115 ,  C12N2501/16 ,  C12N2501/119 ,  C12N2501/415

摘要： The present invention relates to the targeted engineering of specific cell populations. Motoneurons (MN) subtypes display differential vulnerabilities in diseases and in spinal injuries. Engineered MNs of specific rostro-caudal identity represent an important resource for cell therapy approaches. However, these strategies remain impeded by slow and inefficient targeted differentiations due to the imprecise control over cell fate specification in vitro. The inventors now used an embryoid body-based differentiation of hPSC and showed that the HOX clock expression can be controlled to generate subtypes of spinal MNs. Thus, the present invention relates to an in vitro or an ex vivo method for producing spinal neuronal subtypes comprising exposing axial progenitors to retinoic acid (RA), an agonist of Hedgehog signalling pathway, and optionally a FGFR agonist and/or an activator of the TGF pathway, wherein more and more caudal motor neurons identities are obtained by delayed exposure to RA and/or by exposure to RA in combination with the FGFR agonist and/or the activator of the TGF pathway.

公开(公告)号：US11852635B2

公开(公告)日：2023-12-26

申请号：US16461787

申请日：2017-11-16

申请人： Nanosomix, Inc.

发明人： Masato J Mitsuhashi

IPC分类号： G01N33/541 ,  G01N33/68 ,  C07K16/28 ,  C12N5/0793

CPC分类号： G01N33/6896 ,  C07K16/2803 ,  C12N5/0619 ,  G01N33/541 ,  G01N2800/2821

摘要： The present invention relates to methods for quantifying subpopulations of exosomes and diagnostic and prognostic methods for neurodegenerative disorders (e.g., Alzheimer's disease). The invention also provides compositions for quantifying subpopulations of exosomes as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders.

公开(公告)号：US20230392115A1

公开(公告)日：2023-12-07

申请号：US18248739

申请日：2021-10-12

申请人： Research Development Foundation

发明人： Olivier PREYNAT-SEAUVE ,  Karl-Heinz KRAUSE

IPC分类号： C12N5/0793 ,  A61P25/28

CPC分类号： C12N5/0619 ,  A61P25/28 ,  C12N2501/999 ,  C12N2500/99 ,  C12N2533/52 ,  C12N2506/03

摘要： The current disclosure provides for methods for differentiating stem and progenitor cells into neural cells through an approach that excludes the use of SMAD or Noggin inhibition. Aspects of the disclosure relate to a method for differentiating stem or progenitor cells into neural cells, the method comprising contacting the cells with a compound selected from DMH1, DMH2, K02288, A8301, or combinations thereof.